BioSpace News Archive

Drug Development

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19The Company submits Data Access Plan to the FDA to determine potential new clinical endpoints to support Emergency Use Authorization

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine.

June 6, 2022
·
4 min read
Biotech Beach

Valencia Technologies Announces First Commercial Implantation of eCoin® Leadless Tibial Neurostimulator for the Treatment of Urge Urinary Incontinence

Valencia Technologies Corporation, a privately held company, today announced that it has completed the world’s first commercial implantation of eCoin® in Sarasota, FL.

June 6, 2022
·
3 min read
New Study Shows Open-Source Automated Insulin Delivery is a Safe and Effective Treatment Option for People with Type 1 Diabetes

Results from the CREATE Trial demonstrated open-source automated insulin delivery (AID) systems are a safe and effective therapy for people with type 1 diabetes.

June 6, 2022
·
5 min read
Pharm Country

Celldex to Present at the 2022 Jefferies Global Healthcare Conference

Celldex Therapeutics, Inc. announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference in New York City on Wednesday, June 8, 2022 at 8:30 a.m. ET.

June 6, 2022
·
1 min read
Biotech Bay

Tempest to Present at the Jefferies Healthcare Conference - June 06, 2022

Tempest Therapeutics, Inc. announced that management will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 a.m. ET.

June 6, 2022
·
1 min read
BioForest

Singular Genomics and TwinStrand Biosciences Collaborate to Develop Ultra-high Accuracy NGS Solutions for the G4 Platform

Singular Genomics Systems Inc. and TwinStrand Biosciences, Inc. announced a collaboration to develop highly sensitive next generation sequencing solutions for the Singular G4 Sequencing Platform for cutting-edge applications like minimal residual disease detection.

June 6, 2022
·
5 min read
Genetown

Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants

Concert Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share.

June 6, 2022
·
2 min read
Drug Development

Mirati’s KRAS Inhibitor Looks Good, but is it Good Enough to Beat Amgen?

Mirati Therapeutics presented the first clinical data demonstrating CNS-specific activity of a KRASG12C inhibitor in patients with NSCLC with active and untreated CNS metastases.

June 6, 2022
·
2 min read
BioMidwest

Control-IQ Technology Continues to Demonstrate Positive and Sustained Real-World Benefits Across Diverse Cohorts of People with Diabetes

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and sustained benefits in a diverse cohort of people using the t:slim X2™ insulin pump with Control-IQ® technology.

June 6, 2022
·
7 min read
Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in June.

June 6, 2022
·
1 min read